Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Mar 29

PMID 36980528

Authors

Mina Fazel

Armelle Dufresne

Helene Vanacker

Waisse Waissi

Jean-Yves Blay

Mehdi Brahmi

Affiliations

Soon will be listed here.

Abstract

Sarcomas gather a heterogeneous group of mesenchymal malignant tumors including more than 150 different subtypes. Most of them represent aggressive tumors with poor prognosis at the advanced stage, despite the better molecular characterization of these tumors and the development of molecular-driven therapeutic strategies. During the last decade, immunotherapy has been developed to treat advanced cancers, mainly thanks to immune checkpoint inhibitors (ICI) such as anti-PD1/PDL1 and later to adoptive immune cell therapies. In this review, we aim to summarize the state of the art of immunotherapy in soft tissue sarcomas (STS). Overall, the clinical trials of ICI that included a wide diversity of STS subtypes reported limited efficacy with some outlying responders. Both emerging biomarkers are of interest in selecting good candidates and in the development of combination therapies. Finally, the recent breakthroughs of innovative adoptive therapies in STS seem highly promising.

Citing Articles

Principles of Surgical Treatment of Soft Tissue Sarcomas.

Gonzalez M, Mendez-Guerra C, Goh M, Pretell-Mazzini J Cancers (Basel). 2025; 17(3).

PMID: 39941773 PMC: 11816134. DOI: 10.3390/cancers17030401.

Progress in personalized immunotherapy for patients with brain metastasis.

Patel L, Kolundzic N, Abedalthagafi M NPJ Precis Oncol. 2025; 9(1):31.

PMID: 39880875 PMC: 11779815. DOI: 10.1038/s41698-025-00812-0.

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.

Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia S, Morera-Diaz Y, Tewari D Mil Med Res. 2024; 11(1):82.

PMID: 39690423 PMC: 11654217. DOI: 10.1186/s40779-024-00586-9.

Treatment approaches and outcomes of major chest wall resections and reconstructions in patients with soft tissue and bone sarcomas: a retrospective observational study.

Ozaniak A, Galova D, Benesova I, Lischke R, Ozaniak Strizova Z J Thorac Dis. 2024; 16(10):6863-6878.

PMID: 39552892 PMC: 11565326. DOI: 10.21037/jtd-24-472.

A Potential Role for Nivolumab in the Treatment of Fibrous Dysplasia-Related Pain.

Jay M, Hawco C, Clemens K, Van Uum S JCEM Case Rep. 2024; 2(10):luae165.

PMID: 39301179 PMC: 11408923. DOI: 10.1210/jcemcr/luae165.

References

Tomassen T, Weidema M, Hillebrandt-Roeffen M, van der Horst C, Desar I, Flucke U . Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups. Immunol Res. 2022; 70(2):256-268. PMC: 8916989. DOI: 10.1007/s12026-021-09259-4. View

Florou V, Rosenberg A, Wieder E, Komanduri K, Kolonias D, Uduman M . Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019; 7(1):213. PMC: 6686562. DOI: 10.1186/s40425-019-0689-7. View

DAngelo S, Mahoney M, Van Tine B, Atkins J, Milhem M, Jahagirdar B . Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018; 19(3):416-426. PMC: 6126546. DOI: 10.1016/S1470-2045(18)30006-8. View

Zhang S, Kohli K, Black R, Yao L, Spadinger S, He Q . Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res. 2019; 7(8):1237-1243. PMC: 6677581. DOI: 10.1158/2326-6066.CIR-18-0940. View

Couzin-Frankel J . Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013; 342(6165):1432-3. DOI: 10.1126/science.342.6165.1432. View

Andersen R, Thrue C, Junker N, Lyngaa R, Donia M, Ellebaek E . Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 2012; 72(7):1642-50. DOI: 10.1158/0008-5472.CAN-11-2614. View

Livingston M, Jagosky M, Robinson M, Ahrens W, Benbow J, Farhangfar C . Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma. Clin Cancer Res. 2021; 27(23):6424-6431. DOI: 10.1158/1078-0432.CCR-21-2001. View

Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y . Immunogenic Cell Death Induction by Ionizing Radiation. Front Immunol. 2021; 12:705361. PMC: 8417736. DOI: 10.3389/fimmu.2021.705361. View

De Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P . Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One. 2021; 16(2):e0246958. PMC: 7906477. DOI: 10.1371/journal.pone.0246958. View

10.

Huan C, Kelly M, Steele R, Shapira I, Gottesman S, Roman C . Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity. Nat Immunol. 2006; 7(10):1082-91. PMC: 2386253. DOI: 10.1038/ni1378. View

11.

Brahmi M, Vanacker H, Dufresne A . Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond. Curr Opin Oncol. 2020; 32(4):295-300. DOI: 10.1097/CCO.0000000000000652. View

12.

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

13.

Maki R, Jungbluth A, Gnjatic S, Schwartz G, DAdamo D, Keohan M . A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma. 2013; 2013:168145. PMC: 3608267. DOI: 10.1155/2013/168145. View

14.

Tap W, Wagner A, Schoffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo K . Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020; 323(13):1266-1276. PMC: 7139275. DOI: 10.1001/jama.2020.1707. View

15.

Nielsen M, Monberg T, Sundvold V, Albieri B, Hovgaard D, Petersen M . LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma. Oncoimmunology. 2023; 13(1):2290900. PMC: 10732595. DOI: 10.1080/2162402X.2023.2290900. View

16.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

17.

Wilky B, Trucco M, Subhawong T, Florou V, Park W, Kwon D . Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(6):837-848. DOI: 10.1016/S1470-2045(19)30153-6. View

18.

Wagner M, Othus M, Patel S, Ryan C, Sangal A, Powers B . Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021; 9(8). PMC: 8330584. DOI: 10.1136/jitc-2021-002990. View

19.

Petitprez F, De Reynies A, Keung E, Chen T, Sun C, Calderaro J . B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577(7791):556-560. DOI: 10.1038/s41586-019-1906-8. View

20.

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A . STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014; 41(5):843-52. PMC: 5155593. DOI: 10.1016/j.immuni.2014.10.019. View